Human myeloid dendritic cells for cancer therapy: does maturation matter?

. 2010 Jul 19 ; 28 (32) : 5153-60.

Jazyk angličtina Země Nizozemsko Médium print

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/pmid20665974
Odkazy

PubMed 20665974
DOI 10.1016/j.vaccine.2010.05.042
PII: S0264-410X(10)00740-1
Knihovny.cz E-zdroje

Dendritic cells form the connection between innate and adoptive mechanisms of the immune system. As antigen-presenting cells, dendritic cells are capable of presenting tumour antigen and effectively stimulating immune response targeted against a tumour. A number of preclinical and clinical studies document dendritic cells' potential in anti-cancer treatment. Increasing knowledge of dendritic cell biology is leading to improved methods for their preparation for clinical application. Unfortunately, there is to date no consensus specifying optimal conditions for dendritic cell preparation in vitro. This review summarizes the methods used for preparing myeloid dendritic cells derived from monocytic precursors while focusing on cytokine cocktails used for their growth, maturation, and functional adjustment.

Citace poskytuje Crossref.org

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...